United Therapeutics PE ratio UTHR

Share price divided by earnings per share over the last twelve months, since 2011.

Today, Oct 23, 2026: 21.0×
10-year median: 14.1×
Against its 10-year history: 99th; percentile: 0 is its lowest day, 100 its highest
10-year range: 7.3× to 21.9×
Peer median: 37.6×

United Therapeutics' PE ratio is 21.0× as of Oct 23, 2026: a share price of $587.50 against $27.95 of earnings per share over the last twelve months.

That is above its ten-year median of 14.1×, higher than on 99% of days in the last ten years.

Over that time it ranged from 7.3× in Oct 2018 to 21.9× in Dec 2021.

The median for 10 biotech stocks of a similar size is 37.6×.

PE ratio over time

median 14.1×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	21.0×	17.0×	21.1×
2025	19.2×	11.3×	19.6×
2024	15.8×	11.5×	18.0×
2023	12.1×	12.1×	18.8×
2022	18.9×	12.7×	21.7×
2021	21.9×	13.8×	21.9×
2020	14.4×	9.1×	14.4×
2019	7.8×	7.5×	9.6×
2018	8.5×	7.3×	13.2×
2017	13.0×	8.0×	16.0×
2016	9.7×	5.4×	10.9×
2015	12.1×	11.3×	55.7×
2014	38.8×	17.4×	39.3×
2013	20.7×	10.5×	20.7×
2012	10.7×	9.0×	16.8×
2011	15.9×	13.2×	39.6×

Against its peers

Companies in Biotechnology nearest United Therapeutics' size, closest first, today.

Company	PE ratio
UTHRUnited Therapeutics	21.0×
INCYIncyte	14.7×
ALNYAlnylam Pharmaceuticals	37.8×
EXELExelixis	20.3×
ONCBeOne Medicines	67.6×
NBIXNeurocrine Biosciences	20.9×
HALOHalozyme Therapeutics	37.5×
TECHBIO-TECHNE	63.1×
RGENRepligen	242×
KRYSKrystal Biotech	39.0×
REGNRegeneron Pharmaceuticals	19.9×
Peer median	37.6×

Where United Therapeutics ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on United Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.